Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
Background Background
Benefits of prostate cancer (PCa) screening with prostate-specific antigen (PSA) alone are largely offset by excess negative biopsies and overdetection of indolent cancers resulting from the poor specificity of PSA for high-grade PCa (ie, grade group [GG] 2 or greater).
Objectives
To develop a multiplex urinary panel for high-grade PCa and validate its external performance relative to current guideline-endorsed biomarkers.
Development of the optimal 18-gene model for high-grade cancer
Decision curve analysis plots illustrating the net reduction in biopsies
legenda
PHI Prostate Health Index -MPSMyProstateScore 2 gene-MPS2 MyProstateScore 18 geneMPS2+ MyProstateScore 18 gene+ prostate volume
• A new 18-gene PCa test had higher diagnostic accuracy for high-grade PCa relative to existing biomarker tests.
• Clinically, use of this test would have meaningfully reduced unnecessary biopsies performed while maintaining highly sensitive detection of high-grade cancers.
• These data support use of this new PCa biomarker test in patients with elevated PSA levels to reduce the potential harms of PCa screening while preserving its long-term benefits